Pacira BioSciences Stock (NASDAQ: PCRX) stock price, news, charts, stock research, profile.
Open | $29.150 |
Close | $29.220 |
Volume / Avg. | 569.631K / 507.798K |
Day Range | 28.855 - 29.580 |
52 Wk Range | 25.930 - 48.600 |
Market Cap | $1.359B |
P/E Ratio | 32.618 |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 46 |
Short Interest | 12.2% |
Days to Cover | 7.13 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Pacira BioSciences (NASDAQ: PCRX) through any online brokerage.
Other companies in Pacira BioSciences’s space includes: Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), Tarsus Pharmaceuticals (NASDAQ:TARS), Neumora Therapeutics (NASDAQ:NMRA) and ANI Pharmaceuticals (NASDAQ:ANIP).
The latest price target for Pacira BioSciences (NASDAQ: PCRX) was reported by JP Morgan on Thursday, March 7, 2024. The analyst firm set a price target for 45.00 expecting PCRX to rise to within 12 months (a possible 54.00% upside). 24 analyst firms have reported ratings in the last year.
The stock price for Pacira BioSciences (NASDAQ: PCRX) is $29.22 last updated March 28, 2024 at 4:01 PM EDT.
There are no upcoming dividends for Pacira BioSciences.
Pacira BioSciences’s Q4 earnings are confirmed for Thursday, February 23, 2023.
There is no upcoming split for Pacira BioSciences.
Pacira BioSciences is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.